120 results on '"Jacob, Joan"'
Search Results
2. Antitumor Activity of a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting LGR5 in Preclinical Models of Neuroblastoma.
3. The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases.
4. Antibody-drug conjugates targeting EGFR ligand Epiregulin inhibit colorectal tumor growth irrespective ofRASmutational status
5. Figure S3 from Loss of LGR5 through Therapy-induced Downregulation or Gene Ablation Is Associated with Resistance and Enhanced MET-STAT3 Signaling in Colorectal Cancer Cells
6. Supplementary Tables S1-S3 from Loss of LGR5 through Therapy-induced Downregulation or Gene Ablation Is Associated with Resistance and Enhanced MET-STAT3 Signaling in Colorectal Cancer Cells
7. Data from Loss of LGR5 through Therapy-induced Downregulation or Gene Ablation Is Associated with Resistance and Enhanced MET-STAT3 Signaling in Colorectal Cancer Cells
8. Loss of LGR5 through therapy-induced downregulation or gene ablation is associated with resistance and enhanced MET-STAT3 signaling in colorectal cancer cells
9. An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer
10. Abstract 4251: Development and characterization of an epiregulin antibody-drug conjugate for targeting colorectal cancer cell plasticity
11. Loss of LGR5 through plasticity or gene ablation is associated with therapy resistance and enhanced MET-STAT3 signaling in colorectal cancer cells
12. Development of a Novel Combination Therapy targeting MET and LGR5 to overcome Colorectal Cancer Resistance
13. Drug Conjugates of Antagonistic RSPO4 Mutant for Simultaneous Targeting of LGR4/5/6 for Cancer Treatment
14. Phase I Trials with Ormaplatin (Tetraplatin)
15. Drug Conjugates of Antagonistic R-Spondin 4 Mutant for Simultaneous Targeting of Leucine-Rich Repeat-Containing G Protein-Coupled Receptors 4/5/6 for Cancer Treatment
16. Anti-GPR56 monoclonal antibody potentiates GPR56-mediated Src-Fak signaling to modulate cell adhesion
17. The Hippo Pathway in Cardiac Regeneration and Homeostasis: New Perspectives for Cell-Free Therapy in the Injured Heart
18. RELA is sufficient to mediate interleukin‐1 repression of androgen receptor expression and activity in an LNCaP disease progression model
19. RELA is Sufficient to Mediate Interleukin-1 (IL-1) Repression of Androgen Receptor Expression and Activity in LNCaP Disease Progression Model
20. Abstract 2362: NF-κB (p65) mediates interleukin-1 (IL-1) repression of androgen receptor (AR) in AR+prostate cancer (PCa) cell lines
21. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary
22. A pilot trial of chemohormonal therapy for metastatic prostate carcinoma
23. RELA is sufficient to mediate interleukin‐1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
24. Abstract 5749: Interleukin-1 (IL-1) induces a treatment-resistant gene expression pattern in prostate cancer (PCa)
25. Identification of an IL-1-induced gene expression pattern in AR+PCa cells that mimics the molecular phenotype of AR−PCa cells
26. Air-Fluid Level in the Chest X-Ray after Pneumonectomy.
27. Viral Infections and Cell-Mediated Immunity in Immunodeficient Homosexual Men with Kaposi's Sarcoma Treated with Human Lymphoblastoid Interferon
28. Interferon-Induced 2'-5' Oligoadenylate Synthetase during Interferon-α Therapy in Homosexual Men with Kaposi's Sarcoma: Marked Deficiency in Biochemical Response to Interferon in Patients with Acquired Immunodeficiency Syndrome
29. Identification of an IL‐1‐induced gene expression pattern in AR+ PCa cells that mimics the molecular phenotype of AR− PCa cells.
30. Chest Radiology in a COVID Patient with Hypoxia.
31. High-Dose Cisplatin in Hypertonic Saline
32. Carboplatin and Renal Dysfunction
33. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary
34. Providing 'safe conduct': helping your patient cope with cancer
35. CO-OCCURRENCE PATTERNS OF POLYCYCLIC AROMATIC HYDROCARBONS IN SOILS AT HAZARDOUS WASTE SITES
36. A Phase I/II Study of Dose-Intense Paclitaxel with Cisplatin and Cyclophosphamide as Initial Therapy of Poor-Prognosis Advanced-Stage Epithelial Ovarian Cancer
37. A Phase I Study of Paclitaxel and Cyclophosphamide in Recurrent Adenocarcinoma of the Ovary
38. The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factor
39. 5-fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma
40. Confidentiality: A Survey in a Research Hospital
41. Self-assessed learning needs of oncology nurses caring for individuals with HIV-related disorders
42. MALIGNANCIES IN THE AIDS PATIENT: NATURAL HISTORY, TREATMENT STRATEGIES, AND PRELIMINARY RESULTS.
43. Ecological Analysis of Crime Rates and Police Discretion with Young Persons: A Replication
44. Male and Female Youth Crime in Canadian Communities: Assessing the Applicability of Social Disorganization Theory
45. AIDS-related Kaposi's sarcoma: Concepts of care
46. Assessment tool for nurses' learning needs and priorities relative to caring for patients with AIDS and Kaposi's sarcoma
47. Combination chemotherapy of disseminated kaposi's sarcoma in patients with the acquired immune deficiency syndrome
48. Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome. Clinical response and prognostic parameters
49. Documenting patient care in the OR
50. Interferon-Induced 2'-5' Oligoadenylate Synthetase During Interferon-{alpha} Therapy in Homosexual Men with Kaposi's Sarcoma: Marked Deficiency in Biochemical Response to Interferon in Patients with Acquired Immunodeficiency Syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.